focus -WSS

focus

author：focus 2025-09-30 15:15:44 - browse：1322

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Ford recalls 870K F

focus

hotspot

WSS

With trial win, GSK could get blood cancer drug back on market

How to increase colonoscopy rates? Looks like an AI can help

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Public health communication lessons from Covid

See how much Covid

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

focus

focus

leisure time

At least 13 dead in Texas as scorching temps continue

An outrageous hospital charge: I paid $710 for an hour of babysitting

Hepatitis C has a cure — but many Americans still lack access to it

Trump allegedly attempted to have surveillance video deleted: Special Counsel

Wildfire smoke exposes gaps in outdoor worker protections

Public health communication lessons from Covid

Heart attack and stroke risk calculators need revising

Change Healthcare can notify patients about the breach, HHS says

Medical leaders decry Supreme Court decision on affirmative action

ASCO: Palliative care found as helpful given virtually as in person

hotspot

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Intellia reports positive results for its CRISPR

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Behind warning on Apellis’s eye drug lies a conflict of interest

focus

hotspot

Wikipedia

focus